<DOC>
	<DOCNO>NCT01957436</DOCNO>
	<brief_summary>This multi-center phase III study compare clinical benefit androgen deprivation therapy ( +/- docetaxel ) without local radiotherapy without abiraterone acetate prednisone patient metastatic hormone-naïve prostate cancer .</brief_summary>
	<brief_title>A Phase III ADT +/- Docetaxel +/- Local RT +/- Abiraterone Acetate Metastatic Hormone-naïve Prostate Cancer .</brief_title>
	<detailed_description>Eligible patient randomize trial consent form sign , inclusion non-inclusion criterion check . The randomisation result allocation arm A ( ADT ) , arm B ( ADT + Abiraterone ) , arm C ( ADT + radiotherapy ) arm D ( ADT + Abiraterone + radiotherapy ) 1:1:1:1 ratio . The randomization stratify ( minimization ) accord : - enrolment center , - performance status ( 0 vs. 1-2 ) - disease extent : lymph node vs. bone ( without lymph node ) vs. presence visceral metastasis . CRPC define cancer progression ( either confirm PSA rise radiological progression ) serum testosterone castrate level ( &lt; 0.50 ng/mL ) . When CRPC stage reach , castration ( either LHRH agonist LHRH antagonist ) maintain patient . Patients arm B D stop abiraterone ( select case e.g . slow/asymptomatic progression , investigator may consider continue ADT + abirateroneprednisone CRPC , rather switch directly another therapy , patient include abiraterone arm , use prednisone stage leave investigator decision ) . Investigators free manage patient reach CRPC discretion ( use example docetaxel , zoledronic acid , denosumab , sipuleucel-T , radium-223 , cabazitaxel , etc ) accord local us guideline . Abiraterone may use arm A C abiraterone become standard treatment CRPC stage reach .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm adenocarcinoma prostate , 2 . Metastatic disease document positive bone scan CTscan MRI . For patient nodal metastasis , patient extrapelvic enlarge lymph node include either : At least one extrapelvic lymph node ≥ 2 cm extrapelvic lymph node ( ) ≥ 1 cm patient also least one pelvic lymph node ≥ 2 cm 3 . Patients ECOG ≤ 1 ( PS 2 due bone pain accept ) , 4 . Life expectancy ≥ 6 month , 5 . Male age ≥ 18 year old , 6 . Hemoglobin ≥ 10.0 g/dL , 7 . Platelet count ≥ 100,000/μL , 8 . Serum creatinine &lt; 1.5 x ULN calculate creatinine clearance ≥ 60 mL/min , 9 . Serum potassium ≥ 4.0 mmol/L , 10 . Serum bilirubin ≤ 1.5 x ULN ( except document Gilbert 's disease ) ; AST ALT ≤ 2.5 x ULN ( ≤ 5 ULN case liver metastasis ) , 11 . Patients might receive maximum 3 month ADT randomization , 12 . Patients might receive previous radiation therapy direct bone lesion 13 . Patients able take oral medication , 14 . Patients received information sheet sign informed consent form , 15 . Male patient receive study treatment partner childbearing potential advise use method birth control adequate barrier protection ( condom ) determine acceptable study doctor treatment period 4 week last dose study treatment . 16 . Patients must willing able comply schedule visit , treatment plan , laboratory test study procedure , 17 . Patients public private health insurance coverage , Additional criterion patient receive docetaxel : 18 . Patients willing receive docetaxel 19 . Neutrophil ≥ 1500 cells/mm3 20 . Liver function : AST ALT ≤ 1.5 x ULN ; ALP ≤ 2.5 x ULN ; Serum bilirubin ≤ 1.5 x ULN . 21 . Male patient receive docetaxel partner childbearing potential and/or pregnant partner advise use method birth control addition adequate barrier protection ( condom ) determine acceptable study doctor treatment period 6 month last dose docetaxel . 1 . Patients previous local treatment direct prostate primary cancer . A previous TURP allow , 2 . Prior cytotoxic chemotherapy biological therapy treatment prostate cancer , 3 . Any chronic medical condition require high dose corticosteroid 5mg prednisone/prednisolone twice daily , 4 . Active infection medical condition corticosteroid use would contraindicate , 5 . Previously treat ketoconazole prostate cancer 7 day , 6 . Prior systemic treatment azole drug within 4 week randomization , 7 . Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) , 8 . Patients history hypertension except blood pressure control antihypertensive treatment , 9 . Active symptomatic viral hepatitis chronic liver disease ( except Gilbert 's disease ) , 10 . History pituitary adrenal dysfunction , 11 . Small cell carcinoma prostate , 12 . Clinically know significant heart disease ( myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , NYHA Class IIIV heart disease cardiac EF &lt; 50 % baseline , 13 . Atrial Fibrillation , cardiac arrhythmia require therapy , 14 . Other malignancy , except nonmelanoma skin cancer , ≥ 30 % probability recurrence within 24 month , 15 . Known allergy , hypersensitivity intolerance study drug excipients , 16 . Administration investigational therapeutic within 30 day D1 , 17 . Patients already include another therapeutic trial involve experimental drug , 18 . Patients significantly alter mental status prohibit understand study psychological , familial , sociological geographical condition potentially hampering participation , 19 . Individual deprive liberty place authority tutor . Additional criterion patient receive docetaxel : 21 . Patients impaired vision undergo prompt complete ophthalmologic examination . In case Cystoid Macular Oeadema , patient receive docetaxel . 22 . Concomitant use strong CYP3A4 inhibitor ( clarithromycin , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin ) 23 . Allergy taxane</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic hormone-naive</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>abiraterone acetate</keyword>
</DOC>